The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia

Mount Sinai Journal of Medicine

Volumn 64, Issue 1, 1997, Pages 20-25

  Levine, Alice C ^a   Kirschenbaum, Alexander ^a   Lester Gabrilove, J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANOLONE; ANTIANDROGEN; AROMATASE INHIBITOR; ATAMESTANE; CYPROTERONE; ESTROGEN; ETHINYLESTRADIOL; FINASTERIDE; GONADORELIN AGONIST; LEUPRORELIN; NILUTAMIDE; SEX HORMONE; TAMOXIFEN;

CASTRATION; DRUG CHOICE; DRUG MECHANISM; HUMAN; MALE; PATHOGENESIS; PROSTATE HYPERTROPHY; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; ENZYME INHIBITORS; ESTROGEN ANTAGONISTS; ESTROGENS; FINASTERIDE; HUMANS; LEUPROLIDE; MALE; PROSTATIC HYPERPLASIA; TESTOSTERONE;

EID: 0031012053     PISSN: 00272507     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Wilson JD. The pathogenesis of benign prostatic hyperplasia. Am J Med 1990; 68:745-756.
2. Moore RA. Benign hypertrophy and carcinoma of the prostate. Occurrence and experimental production in animals. Surgery 1944; 16:152-167.
3. Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE. Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science 1974; 186:1213-1215.
4. White JW. The results of double castration in hypertrophy of the prostate. Ann Surg 1895; 22:1-80.
5. Cabot AT. The question of castration for enlarged prostate. Ann Surg 1896; 24:265-309.
6. Imperato-McGinley J, Gautier T, Zirinsky K, et al. Prostate visualization studies in males homozygous and heterozygous for 5α-reductase deficiency. N Engl J Med 1992; 327:1185-1191.
7. Siiteri PK, Wilson JD. Dihydrotestosterone in prostatic hypertrophy. I. The formation and content of dihydrotestosterone in the hyperplastic prostate of man. J Clin Invest 1970;49:1737-1745.
8. Levine AC, Wang J-P, Ren M, et al. Immunohistochemical localization of steroid 5α-reductase 2 in the human male fetal reproductive tract and adult prostate. J Clin Endocrinol Metab 1996; 81:384-389.
9. Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992; 327:1185-1191.
10. Stoner E and the Finasteride Study Group. Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994; 43:284-292.
11. Andersen JT, Ekman P, Wolf H, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995; 46:631-637.
12. Lepor H et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. N Engl J Med 1996; 335:533-539.
13. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48:398-405.
14. Kirschenbaum A, Pacheco E, Schuval BJ, Levine AC. Lack of correlation between serum prostate specific antigen or prostate specific antigen density and prostate volume reduction in response to finasteride therapy for benign prostatic hyperplasia. World J Urol In press,
15. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M. Effect of a GnRH analogue (leuprolide) on benign prostatic hypertrophy. J Clin Endocrinol Metab 1987; 64: 1331-1333.
16. Gabrilove JL, Levine AC, Kirschenbaum A, Droller M. Effect of long-acting GnRH analogue (leuprolide) on prostatic size and symptoms in 15 men with benign prostatic hypertrophy. J Clin Endocrinol Metab 1989; 69:629-632.
17. Eri LM, Tveter KJ. Safety, side effects and patient acceptance of the luteinizing hormone releasing hormone agonist leuprolide in treatment of benign prostatic hyperplasia. J Urol 1994; 152:448-452.
18. Matzkin H, Chen J, Lewysohn O, Braf Z. Treatment of benign prostatic hypertrophy by a long-acting gonadotropin-releasing hormone analogue: 1-year experience. J Urol 1991; 145:309-312.
19. Eri LM, Tveter KJ. A prospective, placebo-controlled study of the luteinizing hormone-releasing hormone agonist leuprolide as treatment for patients with benign prostatic hyperplasia. J Urol 1993; 150:359-364.
20. Levine AC, Kirschenbaum A, Kaplan P, et al. Serum prostate-specific antigen levels in patients with benign prostatic hypertrophy treated with leuprolide. Urology 1989; 34:10-13.
21. Levine AC, Ren M, Huber GK, Kirschenbaum AK. The effect of androgen, estrogen, and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates. Endocrinology 1992; 130: 2413-2419.
22. Laroque PA, Prahalada S, Gordon LR, et al. Effects of chronic oral administration of a selective 5α-reductase inhibitor, finasteride, on the dog prostate. Prostate 1994; 24:93-100.
23. Swyer GIM. Postnatal growth changes in the human prostate. J Anat 1944; 78:130-145.
24. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of benign prostatic hyperplasia with age. J Urol 1984; 132:474-479.
25. Pirke KM, Doerr P. Age related changes in interrelationship between plasma testosterone, estradiol and testosterone binding globulin in normal adult males. Acta Endocrinol 1973; 74:729-800.
26. Zumoff B, Strain GW, Kream J, et al. Age variation of the 24-hour mean plasma concentrations of androgens, estrogens and gonadotropins in normal adult men. J Clin Endocrinol Metab 1982; 54:534-538.
27. Zuckerman S. The endocrine control of the prostate. Proc R Soc Med 1936; 29:81-92.
28. Gann PH, Hennekens CH, Longcope C, et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 1995; 26:40-49.
29. Suzuki K et al. Endocrine environment of benign prostatic hyperplasia: prostate size and volume are correlated with serum estrogen concentration. Scand J Urol Nephrol 1995; 29:65-68.
30. McNeal JE. Anatomy of the prostate: an historical survey of divergent views. Prostate 1980; 1:1-13.
31. Meikle AW, Stephenson RA, McWhorter WP, et al. Effects of age, sex steroids, and family relationships on volumes of prostate zones in men with and without prostate cancer. Prostate 1995; 26:253-259.
32. Seppelt U. Correlation among prostate stroma, estrogen levels and urinary estrogen excretion in patients with benign prostatic hypertrophy. J Clin Endocrinol Metab 1978; 47:1230-1235.
33. Kozak I, Bartsch W, Krieg M, Voight KD. Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia. Prostate 1982; 3:433-438.
34. Krieg M, Bartsch W, Thomsen M, Voigt KD. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate. J Steroid Biochem 1983; 19:155-161.
35. Farnsworth WE. Roles of estrogen and SHBG in prostate physiology. Prostate 1996; 28:17-23.
36. Wernert A, Gerdes J, Loy V, et al. Investigations of the estrogen (ER-ICA test) and the progesterone receptor in the prostate and prostatic carcinoma on immunohistochemical basis. Virchows Arch A 1988; 412:387-391.
37. Schulze H, Claus S. Histologic localization of estrogen receptors in normal and diseased human prostates by immunocytochemistry. Prostate 1990; 16:331-343.
38. Kirschenbaum A, Ren M, Erenburg I, et al. Estrogen receptor messenger RNA expression in human benign prostatic hyperplasia: detection, localization and modulation with a long-acting gonadotropin-releasing hormone agonist. J Androl 1994; 15:528-533.
39. Rosner W. Estradiol causes rapid accumulation of c-AMF in human prostate. Proc Natl Acad Sci USA 1994; 91: 5402-5405.
40. Walsh PC, Wilson JD. The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976; 57:1093-1097.
41. Bruengger A, Bartsch G, Hollinger BE, et al. Smooth muscle cell of the canine prostate in spontaneous benign hyperplasia, steroid induced hyperplasia and estrogen or tamoxifen treated dogs. J Urol 1983; 130: 1208-1210.
42. Winter ML, Bosland MC, Wade DR, et al. Induction of benign prostatic hyperplasia in intact dogs by near-physiological levels of 5α-dihydrotestosterone and 17β-estradiol. Prostate 1995; 26:325-333.
43. Eckstein FMP, Zuckerman S. The effect of oestrogenic stimulation on the Mangabey prostate. J Anat 1944; 78:146.
44. Habenicht U-F, El Etreby MF. The periurethral zone of the prostate of the cynomolgos monkey is the most sensitive prostate part for estrogenic stimulus. Prostate 1988; 13:305-316.
45. de Voogt HJ, Rao BR, Geldof AA, et al. Androgen action blockade does not result in reduction in size but changes histology of the normal prostate. Prostate 1987; 11:305-311.
46. Levine AC, Kirschenbaum A, Droller M, Gabrilove JL. Effect of the addition of estrogen to medical castration on prostate size, symptoms, histology, and serum prostate specific antigen levels in four men with benign prostatic hypertrophy. J Urol 1991; 146:790-793.
47. Schweikart H-U, Tunn UW. Effects of the aromatase inhibitor testolactone on human benign prostatic hyperplasia. Steroids 1987; 50:1-3.
48. Gingell JC, Knonagel H, Kurth KH, Tunn UW. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. The Schering 90.062 Study Group. J Urol 1995; 154:399-401.